Which has stronger earnings and valuation, KLRS or SVA?

Kalaris Therapeutics has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is KLRS or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Sinovac Biotech N/A N/A N/A

Does the media prefer KLRS or UPB?

In the previous week, Upstream Bio had 7 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 9 mentions for Upstream Bio and 2 mentions for Kalaris Therapeutics. Upstream Bio's average media sentiment score of 0.51 beat Kalaris Therapeutics' score of 0.51 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KLRS or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Century Therapeutics N/A -49.51% -38.09%

Does the media prefer KLRS or IPSC?

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.07 beat Kalaris Therapeutics' score of 0.51 indicating that Century Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NLTX or KLRS?

Kalaris Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher earnings and valuation, NLTX or KLRS?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is NLTX or KLRS more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media favor FHTX or KLRS?

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 2 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.51 beat Foghorn Therapeutics' score of 0.34 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kalaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kalaris Therapeutics (KLRS) Competitors

$3.94 +0.04 (+1.03%)

As of 04:00 PM Eastern

Compare

KLRS vs. SVA, UPB, IPSC, NLTX, and FHTX

Should you buy Kalaris Therapeutics stock or one of its competitors? Kalaris Therapeutics's main competitors and comparable companies include Sinovac Biotech (SVA), Upstream Bio (UPB), Century Therapeutics (IPSC), Neoleukin Therapeutics (NLTX), and Foghorn Therapeutics (FHTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kalaris Therapeutics compare to Sinovac Biotech?

Kalaris Therapeutics (NASDAQ:KLRS) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Kalaris Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Kalaris Therapeutics and 0 mentions for Sinovac Biotech. Kalaris Therapeutics' average media sentiment score of 0.51 beat Sinovac Biotech's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kalaris Therapeutics	Positive
Sinovac Biotech	Neutral

Sinovac Biotech's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Sinovac Biotech	N/A	N/A	N/A

Kalaris Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kalaris Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kalaris Therapeutics has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Summary

Kalaris Therapeutics beats Sinovac Biotech on 8 of the 12 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Upstream Bio?

Kalaris Therapeutics (NASDAQ:KLRS) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Kalaris Therapeutics presently has a consensus target price of $18.75, indicating a potential upside of 375.89%. Upstream Bio has a consensus target price of $29.67, indicating a potential upside of 387.94%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Kalaris Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Kalaris Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Upstream Bio	$2.85M	116.84	-$143.44M	-$2.90	N/A

66.1% of Kalaris Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 16.5% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Upstream Bio had 7 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 9 mentions for Upstream Bio and 2 mentions for Kalaris Therapeutics. Upstream Bio's average media sentiment score of 0.51 beat Kalaris Therapeutics' score of 0.51 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Summary

Kalaris Therapeutics beats Upstream Bio on 9 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Century Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Kalaris Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Century Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Century Therapeutics	$109.16M	3.47	-$9.58M	-$0.93	N/A

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 2 articles in the media. Century Therapeutics' average media sentiment score of 1.07 beat Kalaris Therapeutics' score of 0.51 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 375.89%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 127.27%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Kalaris Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics' return on equity of -49.51% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Century Therapeutics	N/A	-49.51%	-38.09%

Summary

Century Therapeutics beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Kalaris Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Kalaris Therapeutics and 0 mentions for Neoleukin Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.51 beat Neoleukin Therapeutics' score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Kalaris Therapeutics	Positive

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neoleukin Therapeutics' return on equity of -37.22% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

Summary

Kalaris Therapeutics beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Kalaris Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Foghorn Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Foghorn Therapeutics presently has a consensus target price of $11.43, suggesting a potential upside of 134.67%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kalaris Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	9.36	-$74.28M	-$0.98	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 2 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.51 beat Foghorn Therapeutics' score of 0.34 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Foghorn Therapeutics and Kalaris Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.84M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.95	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.63	16.29	12.89	6.14
Net Income	-$43.44M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-3.90%	-1.37%	-0.33%	-1.47%
1 Month Performance	-2.72%	11.07%	6.51%	2.47%
1 Year Performance	-13.79%	53.71%	25.19%	15.84%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	2.1664 of 5 stars	$3.94 +1.0%	$18.75 +375.9%	-2.5%	$92.84M	N/A	N/A	110
SVA Sinovac Biotech	N/A	$6.47 flat	N/A	N/A	$368.91M	$402.82M	N/A	3,008	High Trading Volume
UPB Upstream Bio	2.053 of 5 stars	$6.71 -1.2%	$29.67 +342.1%	-68.0%	$367.51M	$3.16M	N/A	38	News Coverage Analyst Forecast
IPSC Century Therapeutics	2.0383 of 5 stars	$2.02 -9.4%	$4.75 +135.1%	+339.6%	$365.77M	N/A	N/A	170	Positive News
NLTX Neoleukin Therapeutics	N/A	$37.86 -1.4%	N/A	+104.9%	$355.81M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. SVA, UPB, IPSC, NLTX, and FHTX

How does Kalaris Therapeutics compare to Sinovac Biotech?

Summary

How does Kalaris Therapeutics compare to Upstream Bio?

Summary

How does Kalaris Therapeutics compare to Century Therapeutics?

Summary

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Kalaris Therapeutics compare to Foghorn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. SVA, UPB, IPSC, NLTX, and FHTX

How does Kalaris Therapeutics compare to Sinovac Biotech?

Which has more volatility and risk, KLRS or SVA?

Does the media favor KLRS or SVA?

Is KLRS or SVA more profitable?

Do analysts recommend KLRS or SVA?

Do institutionals and insiders hold more shares of KLRS or SVA?

Which has stronger earnings and valuation, KLRS or SVA?

Summary

How does Kalaris Therapeutics compare to Upstream Bio?

Do analysts recommend KLRS or UPB?

Which has more risk & volatility, KLRS or UPB?

Which has preferable valuation and earnings, KLRS or UPB?

Do insiders and institutionals believe in KLRS or UPB?

Does the media prefer KLRS or UPB?

Is KLRS or UPB more profitable?

Summary

How does Kalaris Therapeutics compare to Century Therapeutics?

Which has more risk & volatility, KLRS or IPSC?

Do insiders and institutionals have more ownership in KLRS or IPSC?

Which has better earnings & valuation, KLRS or IPSC?

Does the media prefer KLRS or IPSC?

Do analysts prefer KLRS or IPSC?

Is KLRS or IPSC more profitable?

Summary

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Do analysts recommend NLTX or KLRS?

Does the media refer more to NLTX or KLRS?

Do insiders and institutionals hold more shares of NLTX or KLRS?

Is NLTX or KLRS more profitable?

Which has higher earnings and valuation, NLTX or KLRS?

Which has more risk and volatility, NLTX or KLRS?

Summary

How does Kalaris Therapeutics compare to Foghorn Therapeutics?

Is FHTX or KLRS more profitable?

Which has more volatility & risk, FHTX or KLRS?

Do analysts prefer FHTX or KLRS?

Do insiders & institutionals have more ownership in FHTX or KLRS?

Which has higher valuation & earnings, FHTX or KLRS?

Does the media favor FHTX or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools